Literature DB >> 17036183

[Exercise in arterial hypertension].

Hans-Georg Predel1, Thomas Schramm.   

Abstract

Regular endurance training has established itself as a major therapeutic principle in the specter of nonpharmacological measures in arterial hypertension. An initial medical check as well as an adequate technique, dosage and intensity of the prescribed exercise training are mandatory. With respect to the concomitant pharmacological treatment, it should be considered that the beneficial effects of lifestyle modification will not be counteracted by the chosen antihypertensive drug but, ideally, synergistically supported. Based on the individual clinical situation, principally all antihypertensive drugs recommended by the current European guidelines, may be prescribed as mono- or combination therapy.beta-receptor blockers are especially capable of controlling excessive exercise-induced blood pressure increase; however, they have metabolic and exercise physiological limitations. The neutrality concerning metabolic and exercise physiological parameters as well as the positive profile of side effects favor ACE inhibitors, long-acting calcium channel blockers and especially AT(1) antagonists in physically active hypertensive patients with concomitant metabolic syndrome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17036183     DOI: 10.1007/s00059-006-2889-4

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  3 in total

Review 1.  [Physical activity for prevention and therapy of internal diseases in the elderly].

Authors:  Burkhard Weisser; Manuela Preuss; Hans-Georg Predel
Journal:  Med Klin (Munich)       Date:  2009-04-15

2.  Cardiovascular prevention in clinical practice (ESC and German guidelines 2007).

Authors:  Helmut Gohlke; Christian Albus; Detlef Bernd Gysan; Harry W Hahmann; Peter Mathes
Journal:  Herz       Date:  2009-02       Impact factor: 1.443

3.  [Management of hypertension (ESC Guideline 2007/DHL Guideline 2008)].

Authors:  Timothy Krauss; Heribert Schunkert
Journal:  Herz       Date:  2009-02       Impact factor: 1.443

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.